NewsRoom Articles - Page 38 of 593

MondayJul 29, 2024 10:00 am

Congress Could Be Quickest Way to Reclassify Marijuana

Earlier this month, the United States Supreme Court thrust cannabis rescheduling into even deeper uncertainty. This comes after the court’s ruling directed that no deference be afforded to how federal agencies interpreted laws when Congress left room for ambiguity. This move may have increased the time it will take to reschedule marijuana because it offered new lines of attack to those what oppose the move. It is expected that the opposition could use the Loper v. Bright ruling, among other attacks, to hinder progress on rescheduling. This comes after President Joe Biden directed that the U.S. Department of Health and…

FridayJul 26, 2024 4:20 pm

420 with CNW — New Study Reports Patients Say Marijuana More Helpful for Musculoskeletal Pain Than Conventional Medications

A recent study highlights that more than 20% of patients visiting orthopedic surgeons for chronic musculoskeletal (MSK) pain have turned to marijuana for relief. Among these individuals, nearly two-thirds found marijuana to be somewhat effective, and more than 90% reported at least slight effectiveness. The study indicates that 57% of patients considered cannabis more effective than other pain medications, with 40% reducing their use of other analgesics since starting cannabis. However, only 26% had cannabis recommended by a physician for their MSK pain. The most frequently used cannabinoid among the patients was CBD, with 39% favoring it. Another 20% preferred…

FridayJul 26, 2024 10:00 am

New Survey Shows Cannabis Could Reduce Prescription Analgesic Use

The state of Ohio legalized the medical use of cannabis in 2016, making it the 25th state in the country to do so. As of March 2024, the state had registered 167,153 patients who were legally allowed to use medical cannabis. Ohio’s medical cannabis program covers 26 eligible conditions, including post-traumatic stress disorder (“PTSD”) and chronic and intractable or severe pain, among others. The program permits cannabis to be sold as edibles, tinctures, oils, plant material and patches in 124 dispensaries across Ohio. Now, a recently conducted survey has discovered that the majority of medical marijuana patients have observed a…

ThursdayJul 25, 2024 4:20 pm

420 with CNW — Kentucky Governor Writes to DEA Admin Supporting Federal Marijuana Reform

Kentucky Governor Andy Beshear recently wrote to Anne Milgram, the U.S. Drug Enforcement Administration (DEA) administrator, to voice his backing of the Department of Health and Human Services’ proposal to relax cannabis restrictions. The proposal advocates for moving marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act (CSA). Governor Beshear highlighted that this reclassification would offer patients a safer alternative to harmful opioids, ensuring continued access to reliable products. He also noted that such a move would aid communities in reducing illegal drug use and crime. Additionally, it would level the economic playing field for marijuana businesses…

WednesdayJul 24, 2024 4:20 pm

420 with CNW — Marijuana Companies in Europe Consider Listing in US as Rescheduling Progresses

A number of European marijuana start-ups are thinking about listing in New York due to the anticipated reclassification of marijuana by federal authorities as a less harmful narcotic. Although the companies haven’t finalized their plans, they are drawn to the U.S. market’s increasingly favorable stance on cannabis and CBD products. Statista estimates that this year’s CBD market might be valued at approximately $6.90 billion. Under the new U.S. regulations, cannabis may be moved from the highly restrictive Schedule 1 of the Controlled Substances Act (CSA), which also includes LSD, heroin, and fentanyl, to the less restrictive Schedule 3, placing it…

WednesdayJul 24, 2024 10:00 am

State Cannabis Regulators Urge Feds to Provide Clarity Regarding Reclassification

The Cannabis Regulators Association (CANNRA) is requesting that the U.S. Drug Enforcement Administration and Biden Administration offer clarity on how rescheduling cannabis will affect enforcement by the federal government, particularly in legal states. In a public comment to the DEA’s administrator Anne Milgram, CANNRA leaders explained that without federal guidance, territorial and state government agencies would be left guessing and hypothesizing about these dynamics and their possible effects on legal programs regulated by states, and the populations impacted by these programs in various jurisdictions, among other things. CANNRA is an organization that represents hemp and cannabis regulators in more than…

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

TuesdayJul 23, 2024 4:20 pm

420 with CNW — Curaleaf, Other MSOs Switching to Hemp-Sourced THC

Curaleaf Holdings had decided to step away from hemp. The New York-based cannabis multistate operator initially ran a hemp farm in Lexington, Kentucky, for its CBD product line starting in 2018. According to its annual filings, Curaleaf terminated its lease, stopped all hemp-related manufacturing and wholesale operations in Kentucky by the end of September last year and listed its assets for sale. However, Curaleaf recently reentered the hemp business, following a larger cannabis industry trend for licensed businesses. The company introduced a new range of THC-derived hemp products on June 24, 2024, under The Hemp Co. brand. The hemp-based, shelf-stable…

MondayJul 22, 2024 4:20 pm

420 with CNW — Recent Supreme Court Decision Could Impact Marijuana Reclassification

The recent decision by the U.S. Supreme Court to limit the power of federal regulatory agencies has introduced new uncertainty regarding the future of cannabis rescheduling. However, administrative law and policy experts believe that the ambiguity is not expected to hinder the Biden administration’s reclassification process. In a 6-to-3 decision last Friday, the court ruled that courts are no longer obligated to follow federal agencies’ interpretations of statutes when Congress leaves those interpretations unclear. This ruling effectively ends the Chevron doctrine, named after a 1984 judgment. Historically, courts would defer to regulators as the subject matter experts. There is speculation…

MondayJul 22, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream Results from the GLP-1-H24-2 study are set to be announced in late August or early September Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2.…